Interleukin-1 stimulates ADAM17 through a mechanism independent of its cytoplasmic domain or phosphorylation at threonine 735

PLoS ONE

Volumn 7, Issue 2, 2012, Pages

  Hall, Katherine C ^a,b   Blobel, Carl P ^a,b  

^a HOSPITAL FOR SPECIAL SURGERY   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ADAM PROTEIN; ADAM10 ENDOPEPTIDASE; ADAM17 PROTEIN; ANISOMYCIN; INTERLEUKIN 1BETA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MUTANT PROTEIN; THREONINE; TRANSFORMING GROWTH FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; G PROTEIN COUPLED RECEPTOR; INTERLEUKIN 1; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; TUMOR NECROSIS FACTOR-ALPHA CONVERTASE;

ANIMAL CELL; ARTICLE; CELL STIMULATION; CONTROLLED STUDY; FIBROBLAST; MOUSE; MUTATION; NONHUMAN; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; ANIMAL; CHEMISTRY; CHO CELL; CYTOLOGY; CYTOPLASM; HAMSTER; HUMAN; METABOLISM; PHOSPHORYLATION; PROTEIN TERTIARY STRUCTURE; TRANSGENE; TRANSGENIC MOUSE;

ADAM PROTEINS; ANIMALS; ANISOMYCIN; CHO CELLS; CRICETINAE; CYTOPLASM; FIBROBLASTS; HUMANS; INTERLEUKIN-1; MICE; MICE, TRANSGENIC; PHOSPHORYLATION; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, G-PROTEIN-COUPLED; THREONINE; TRANSGENES;

EID: 84857597018     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0031600     Document Type: Article

References (40)

1. Black R, Rauch CT, Kozlosky CJ, Peschon JJ, Slack JL, et al. (1997) A metalloprotease disintegrin that releases tumour-necrosis factor-α from cells. Nature 385: 729-733.
2. Horiuchi K, Kimura T, Miyamoto T, Takaishi H, Okada Y, et al. (2007) Cutting Edge: TNF-α-Converting Enzyme (TACE/ADAM17) Inactivation in Mouse Myeloid Cells Prevents Lethality from Endotoxin Shock. J Immunol 179: 2686-2689.
3. Moss ML, Jin S-LC, Milla ME, Burkhart W, Cartner HL, et al. (1997) Cloning of a disintegrin metalloproteinase that processes precursor tumour-recrosis factor-α. Nature 385: 733-736.
4. Bell J, Herrera AH, Li Y, Walcheck B, (2007) Role of ADAM17 in the ectodomain shedding of TNF-α and its receptors by neutrophils and macrophages. J Leukoc Biol 82.
5. Blobel CP, (2005) ADAMs: key players in EGFR-signaling, development and disease. Nat Rev Mol Cell Bio 6: 32-43.
6. Jackson LF, Qiu TH, Sunnarborg SW, Chang A, Zhang C, et al. (2003) Defective valvulogenesis in HB-EGF and TACE-null mice is associated with aberrant BMP signaling. Embo J 22: 2704-2716.
7. Peschon JJ, Slack JL, Reddy P, Stocking KL, Sunnarborg SW, et al. (1998) An essential role for ectodomain shedding in mammalian development. Science 282: 1281-1284.
8. Sahin U, Weskamp G, Zhou HM, Higashiyama S, Peschon JJ, et al. (2004) Distinct roles for ADAM10 and ADAM17 in ectodomain shedding of six EGFR-ligands. J Cell Biol 164: 769-779.
9. Sternlicht MD, Sunnarborg SW, Kouros-Mehr H, Yu Y, Lee DC, et al. (2005) Mammary ductal morphogenesis requires paracrine activation of stromal EGFR via ADAM17-dependent shedding of epithelial amphiregulin. Development 132: 3923-3933.
10. Murphy G, (2008) The ADAMs: signalling scissors in the tumour microenvironment. Nat Rev Cancer 12: 929-941.
11. Weskamp G, Mendelson K, Swendeman S, Le Gall S, Ma Y, et al. (2010) Pathological Neovascularization Is Reduced by Inactivation of ADAM17 in Endothelial Cells but Not in Pericytes. Circ Res 106: 932-940.
12. Chalaris A, Adam N, Sina C, Rosenstiel P, Lehmann-Koch J, et al. (2010) Critical role of the disintegrin metalloprotease ADAM17 for intestinal inflammation and regeneration in mice. J Exp Med 207: 1617-1624.
13. Reddy P, Slack JL, Davis R, Cerretti DP, Kozlosky CJ, et al. (2000) Functional analysis of the domain structure of tumor necrosis factor-alpha converting enzyme. J Biol Chem 275: 14608-14614.
14. Horiuchi K, Le Gall S, Schulte M, Yamaguchi T, Reiss K, et al. (2007) Substrate Selectivity of EGF-Receptor Ligand Sheddases and Their Regulation by Phorbol Esters and Calcium Influx. Mol Biol Cell 18: 176-188.
15. Le Gall SM, Maretzky T, Issuree PDA, Niu X-D, Reiss K, et al. (2010) ADAM17 is regulated by a rapid and reversible mechanism that controls access to its catalytic site. J Cell Science 123: 3913-3922.
16. Maretzky T, Evers A, Zhou W, Swendeman SL, Wong PM, et al. (2011) Migration of growth factor-stimulated epithelial and endothelial cells depends on EGFR transactivation by ADAM17. Nat Commun 2: 229.
17. Swendeman S, Mendelson K, Weskamp G, Horiuchi K, Deutsch U, et al. (2008) VEGF-A stimulates ADAM17-dependent shedding of VEGFR2 and crosstalk between VEGFR2 and ERK signaling. Circ Res 103: 916-918.
18. Ohtsu H, Dempsey PJ, Frank GD, Brailoiu E, Higuchi S, et al. (2006) ADAM17 mediates epidermal growth factor receptor transactivation and vascular smooth muscle cell hypertrophy induced by angiotensin II. Arterioscler Thromb Vasc Biol 26: e133-137.
19. Gschwind A, Hart S, Fischer OM, Ullrich A, (2003) TACE cleavage of proamphiregulin regulates GPCR-induced proliferation and motility of cancer cells. Embo J 22: 2411-2421.
20. Hart S, Fischer OM, Ullrich A, (2004) Cannabinoids induce cancer cell proliferation via tumor necrosis factor alpha-converting enzyme (TACE/ADAM17)-mediated transactivation of the epidermal growth factor receptor. Cancer Res 64: 1943-1950.
21. Maretzky T, Zhou W, Huang XY, Blobel CP, (2011) A transforming Src mutant increases the bioavailability of EGFR ligands via stimulation of the cell-surface metalloproteinase ADAM17. Oncogene 30: 611-618.
22. Diaz-Rodriguez E, Montero JC, Esparis-Ogando A, Yuste L, Pandiella A, (2002) Extracellular signal-regulated kinase phosphorylates tumor necrosis factor alpha-converting enzyme at threonine 735: a potential role in regulated shedding. Mol Biol Cell 13: 2031-2044.
23. Rousseau S, Papoutsopoulou M, Symons A, Cook D, Lucocq JM, et al. (2008) TPL2-mediated activation of ERK1 and ERK2 regulates the processing of pre-TNF alpha in LPS-stimulated macrophages. J Cell Sci 121: 149-154.
24. Fan H, Turck CW, Derynck R, (2003) Characterization of growth factor-induced serine phosphorylation of tumor necrosis factor-alpha converting enzyme and of an alternatively translated polypeptide. J Biol Chem 278: 18617-18627.
25. Zhang Q, Thomas SM, Lui VW, Xi S, Siegfried JM, et al. (2006) Phosphorylation of TNF-alpha converting enzyme by gastrin-releasing peptide induces amphiregulin release and EGF receptor activation. Proc Natl Acad Sci U S A 103: 6901-6906.
26. Wang SE, Xiang B, Guix M, Olivares MG, Parker J, et al. (2008) Transforming growth factor beta engages TACE and ErbB3 to activate phosphatidylinositol-3 kinase/Akt in ErbB2-overexpressing breast cancer and desensitizes cells to trastuzumab. Mol Cell Biol 28: 5605-5620.
27. Xu P, Derynck R, (2010) Direct activation of TACE-mediated ectodomain shedding by p38 MAP kinase regulates EGF receptor-dependent cell proliferation. Mol Cell 37: 551-566.
28. Zheng Y, Saftig P, Hartmann D, Blobel C, (2004) Evaluation of the contribution of different ADAMs to TNFα shedding and of the function of the TNFα ectodomain in ensuring selective stimulated shedding by the TNFα convertase (TACE/ADAM17). J Biol Chem 279: 42898-42906.
29. Zheng Y, Schlondorff J, Blobel CP, (2002) Evidence for Regulation of the Tumor Necrosis Factor alpha-Convertase (TACE) by Protein-tyrosine Phosphatase PTPH1. J Biol Chem 277: 42463-42470.
30. Schlöndorff JS, Lum L, Blobel CP, (2001) Biochemical and pharmacological criteria define two shedding activities for TRANCE/OPGL that are distinct from the TNFα convertase (TACE). J Biol Chem 276: 14665-14674.
31. Sahin U, Weskamp G, Zheng Y, Chesneau V, Horiuchi K, et al. (2006) A sensitive method to monitor ectodomain shedding of ligands of the epidermal growth factor receptor. In: Patel TB, Bertics PJ, editors. Epidermal Growth Factor: Methods and Protocols Totowa, NJ Humana Press Inc pp. 99-113.
32. Schlöndorff J, Becherer JD, Blobel CP, (2000) Intracellular maturation and localization of the tumour necrosis factor alpha convertase (TACE). Biochem J 347 Pt 1: 131-138.
33. Arribas J, Coodly L, Vollmer P, Kishimoto TK, Rose-John S, et al. (1996) Diverse cell surface protein ectodomains are shed by a system sensitive to metalloprotease inhibitors. J Biol Chem 271: 11376-11382.
34. Arribas J, Massague J, (1995) Transforming growth factor-α and β-amyloid precursor share a secretory mechanism. J Cell Biol 128: 433-441.
35. Weskamp G, Krätzschmar JR, Reid M, Blobel CP, (1996) MDC9, a widely expressed cellular disintegrin containing cytoplasmic SH3 ligand domains. J Cell Biol 132: 717-726.
36. Le Gall S, Bobe P, Reiss K, Horiuchi K, Niu X-D, et al. (2009) ADAMs 10 and 17 represent differentially regulated components of a general shedding machinery for membrane proteins such as TGFα, L-Selectin and TNFα. Mol Biol Cell 20: 1785-1794.
37. Li X, Fan H, (2004) Loss of ectodomain shedding due to mutations in the metalloprotease and cysteine-rich/disintegrin domains of the tumor necrosis factor-alpha converting enzyme (TACE). J Biol Chem 279: 27365-27375.
38. Doedens JR, Black RA, (2000) Stimulation-induced down-regulation of tumor necrosis factor-alpha converting enzyme. J Biol Chem 275: 14598-14607.
39. Li X, Perez L, Fan H, (2011) Inhibitory role of TACE/ADAM17 cytotail in protein ectodomain shedding. World J Biol Chem 2: 246-251.
40. Gosset M, Berenbaum F, Thirion S, Jacques C, (2008) Primary culture and phenotyping of murine chondrocytes. Nat Protoc 3: 1253-1260.